Gnubiotics joins the fight against COVID-19
Share this article
Gnubiotics accelerates testing of multivalent-glycan based pipeline candidates against viral entry of COVID-19
Since 2016, Gnubiotics has invested in understanding the science of glycans, specifically their natural properties of selective microbiome modulation. This understanding of glycan structure combined with efficacy data generated on microbial function has prompted Gnubiotics response to join the global fight against COVID-19.
In collaboration with the Institute Antiviral Research at Utah State University, Gnubiotics has accelerated pre-clinical trials to explore the effects of its multivalent glycan formulations on live SARS-CoV-2 viruses in cell culture as well as evaluating the inhibition of viral- induced cytopathic effects (CPE).